Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)

被引：13

作者：

Zboralski, D. ^{[1
]}

Osterkamp, F. ^{[2
]}

Simmons, A. D. ^{[3
]}

Bredenbeck, A. ^{[4
]}

Schumann, A. ^{[4
]}

Paschke, M. ^{[5
]}

Beindorff, N. ^{[6
]}

Mohan, A-M. ^{[7
]}

Nguyen, M. ^{[3
]}

Xiao, J. ^{[8
,9
]}

Harding, T. C. ^{[3
]}

Hoehne, A. ^{[10
]}

Reineke, U. ^{[11
]}

Smerling, C. ^{[12
]}

机构：

[1] 3B Pharmaceut GmbH, Assay Unit, Berlin, Germany

[2] 3B Pharmaceut GmbH, Chem & Analyt, Berlin, Germany

[3] Clovis Oncol Inc, Translat Med, Boulder, CO USA

[4] 3B Pharmaceut GmbH, Nucl Med, Berlin, Germany

[5] 3B Pharmaceut GmbH, Biol & Assay Dev, Berlin, Germany

[6] Charite Univ Med Berlin, Berlin Expt Radionuclide Imaging Ctr BERIC, Berlin, Germany

[7] Charite Univ Med Berlin, Dept Nucl Med, Berlin, Germany

[8] Clovis Oncol Inc, Clin Pharmacol, Boulder, CO USA

[9] Clovis Oncol Inc, DMPK, Boulder, CO USA

[10] 3B Pharmaceut GmbH, Radiopharmaceut Technol, Berlin, Germany

[11] 3B Pharmaceut GmbH, Berlin, Germany

[12] 3B Pharmaceut GmbH, Nucl Med & Imaging, Berlin, Germany

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.685

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

571P

引用

页码：S488 / S488

页数：1